ATE378590T1 - Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie - Google Patents

Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie

Info

Publication number
ATE378590T1
ATE378590T1 AT01956629T AT01956629T ATE378590T1 AT E378590 T1 ATE378590 T1 AT E378590T1 AT 01956629 T AT01956629 T AT 01956629T AT 01956629 T AT01956629 T AT 01956629T AT E378590 T1 ATE378590 T1 AT E378590T1
Authority
AT
Austria
Prior art keywords
iia
class
identifying
peptide
subdominant
Prior art date
Application number
AT01956629T
Other languages
English (en)
Inventor
Kostas Kosmatopoulos
Sophie Tourdot
Antonio Scardino
David Gross
Original Assignee
Inst Nat Sante Rech Med
Inst Gustave Roussy Igr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Inst Gustave Roussy Igr filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE378590T1 publication Critical patent/ATE378590T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
AT01956629T 2000-07-21 2001-07-20 Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie ATE378590T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0009591A FR2812087B1 (fr) 2000-07-21 2000-07-21 Procede de criblage de peptides utilisables en immunotherapie

Publications (1)

Publication Number Publication Date
ATE378590T1 true ATE378590T1 (de) 2007-11-15

Family

ID=8852782

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01956629T ATE378590T1 (de) 2000-07-21 2001-07-20 Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie

Country Status (11)

Country Link
US (2) US7425606B2 (de)
EP (1) EP1309860B1 (de)
AT (1) ATE378590T1 (de)
AU (1) AU2001278555A1 (de)
CA (1) CA2416761C (de)
DE (1) DE60131413T2 (de)
DK (1) DK1309860T3 (de)
ES (1) ES2296778T3 (de)
FR (1) FR2812087B1 (de)
PT (1) PT1309860E (de)
WO (1) WO2002008716A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
KR20070057273A (ko) 2000-02-04 2007-06-04 듀크 유니버시티 인체 면역결핍 바이러스 백신
US7388071B2 (en) * 2000-02-15 2008-06-17 The Regents Of The University Of California Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
EP1752160A3 (de) * 2001-04-06 2007-05-30 Mannkind Corporation Epitop-Sequenzen
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
DE602006006046D1 (de) * 2005-05-09 2009-05-14 Vaxon Biotech Verwendung nativer peptide und deren optimierter derivate zur impfung
EP1962889B1 (de) * 2005-12-23 2009-07-08 Vaxon Biotech Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
EP1887084A1 (de) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmide mit immunologischer Wirkung
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
US20140099341A1 (en) 2011-05-26 2014-04-10 Alfred E. Slanetz Modulated Immunodominance Therapy
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128319A (en) * 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
AU2287595A (en) * 1994-04-11 1995-10-30 Ixsys, Inc. Class i peptide binding motifs
EP1612555B1 (de) * 1996-03-21 2008-10-22 Circassia Limited Verwendung von kryptischen Peptiden zur Induktion von immunologischer Toleranz
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
WO2000025813A1 (en) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
US7388071B2 (en) * 2000-02-15 2008-06-17 The Regents Of The University Of California Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie

Also Published As

Publication number Publication date
US7425606B2 (en) 2008-09-16
AU2001278555A1 (en) 2002-02-05
ES2296778T3 (es) 2008-05-01
DE60131413T2 (de) 2008-09-04
FR2812087A1 (fr) 2002-01-25
US7976843B2 (en) 2011-07-12
PT1309860E (pt) 2008-02-25
WO2002008716A3 (fr) 2003-02-27
WO2002008716A2 (fr) 2002-01-31
FR2812087B1 (fr) 2007-05-11
US20040072240A1 (en) 2004-04-15
CA2416761A1 (fr) 2002-01-31
CA2416761C (fr) 2013-04-23
EP1309860A2 (de) 2003-05-14
EP1309860B1 (de) 2007-11-14
US20090269363A1 (en) 2009-10-29
DE60131413D1 (de) 2007-12-27
DK1309860T3 (da) 2008-03-17

Similar Documents

Publication Publication Date Title
ATE468127T1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
ATE378590T1 (de) Verfahren zum auffinden von peptiden zur verwendung in der immuntherapie
Zee et al. Efficient mapping and characterization of a T cell epitope by the simultaneous synthesis of multiple peptides
HRP20160915T1 (hr) Nova imunoterapija protiv nekoliko tumora uključujući neuronske tumore i tumore mozga
Bulinski et al. Peptide antibody specific for the amino terminus of skeletal muscle alpha-actin.
CY1105282T1 (el) Διαγνωση της κοιλιοκακης με τη χρηση ενος επιτοπιου της γλιαδινης
GB2439474A (en) LI-Key/Antigenic epitope hybrid peptide vaccines
JPH1066564A (ja) 抗原特異的活性化ｔ細胞
ATE546533T1 (de) Rekombinante expression von proteinen in einer disulfidverbrückten, zweikettigen form
KR840008693A (ko) 재조합 기법에 의한 면역글로블린의 제조 및 면역글로블린 아미노산 서열의 조합방법
ATE366814T1 (de) Gl50 moleküle, sowie verwendungen derselben
DK1037917T3 (da) Rekombinante nodavirus sammensætninger og fremgangsmåder
CA2420350A1 (en) Membrane penetrating peptides and uses thereof
CA2248667A1 (en) Hla-a2.1 binding peptides and their uses
Melief et al. Potential immunogenicity of oncogene and tumor suppressor gene products
DE60144021D1 (de) Für zellzyklusproteine kodierende nukleinsäure und deren verwendung
CA2542104A1 (en) Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
RU2017134506A (ru) Система презентации пептидов на клеточной поверхности
AP2368A (en) Novel expression vectors and uses thereof.
Stewart et al. Protein NH2-terminal asparagine deamidase. Isolation and characterization of a new enzyme.
DE69836647D1 (de) Methode zur herstellung von (poly)peptiden unter verwendung von verkürzten varianten von sv40 'large' t antigen mit einem intakten n terminus
CA2819978A1 (en) Immune restricted peptides with increased efficacy
TW581812B (en) Assay for the diagnosis of schizophrenia based on a new peptide
WO2003070768A3 (en) Cd40 splice variants,method of detection thereof, compositions comprising said variant(s) or nucleic acid encoding the same and use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1309860

Country of ref document: EP